Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 11/20 | 1.00 |
| ▸ | CDK2 | P24941 | 3/20 | 1.00 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.72 |
| ▸ | CCNA1 | P78396 | 1/20 | 0.72 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.68 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.67 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.65 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.62 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.59 |
| ▸ | YTHDC1 | Q96MU7 | 1/20 | 0.59 |
| ▸ | STAT3 | P40763 | 1/20 | 0.59 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4524085 | 0.91 | FLT3 (0.83) | FLT3CDK2CCNA2CCNA1ADORA3 | |
| SCHEMBL951125 | 0.84 | FLT3 (1.00) | FLT3CDK2CCNA2CCNA1CSNK2A1 | |
| SCHEMBL30398090 | 0.84 | FLT3 (1.00) | FLT3CDK2CCNA2CCNA1CSNK2A1 | |
| SCHEMBL29365548 | 0.83 | FLT3 (0.81) | FLT3CDK2CCNA2CCNA1CSNK2A1 | |
| SCHEMBL4509961 | 0.82 | FLT3 (0.78) | FLT3CDK2CCNA2CCNA1ADORA3 | |
| SCHEMBL29732692 | 0.82 | FLT3 (0.78) | FLT3CDK2CCNA2CCNA1CSNK2A1 | |
| SCHEMBL4523169 | 0.82 | FLT3 (0.89) | FLT3CDK2CCNA2CCNA1CSNK2A1 | |
| SCHEMBL954669 | 0.82 | FLT3 (0.78) | FLT3CDK2CCNA2CCNA1CSNK2A1 | |
| SCHEMBL14699151 | 0.82 | ITK (0.79) | FLT3CDK2CCNA2CCNA1SMN1; SMN2 | |
| SCHEMBL30026349 | 0.81 | FLT3 (0.81) | FLT3CDK2CCNA2CCNA1CSNK2A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110021467-A1 | INDAZOLECARBOXAMIDE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF MALARIA | SANOFI-AVENTIS (FR) | 2011-01-27 | — | — | US | disclosed |
| US-7842711-B2 | Indazolecarboxamide derivatives for the treatment and prevention of malaria | SANOFI-AVENTIS (FR) | 2010-11-30 | — | — | US | disclosed |
| US-20070185187-A1 | INDAZOLECARBOXAMIDE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF MALARIA | SANOFI-AVENTIS (FR) | 2007-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070185187-A1 | INDAZOLECARBOXAMIDE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF MALARIA | CYP3A43, CYP3A5, SIRT5 | FLT3 1154/4885CDK2 3323/4885CCNA2 4122/4885 |
| US-20110021467-A1 | INDAZOLECARBOXAMIDE DERIVATIVES FOR THE TREATMENT AND PREVENTION OF MALARIA | CYP3A43, CYP3A5, SIRT5 | FLT3 1154/4885CDK2 3323/4885CCNA2 4122/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.